Jeha Jeon

Jeha Jeon

Auto-generated profile, based on publicly available information

Jeha Jeon

Molecular Neurobiology Laboratory, Department of Psychiatry and McLean Hospital, Harvard Medical School, Belmont, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2020 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
JSJeffrey Schweitzer
Jeffrey Schweitzer
BSBin Song
Bin Song
THTodd M. Herrington
Todd M. Herrington
TPTae-Yoon Park
Tae-Yoon Park
NLNayeon Lee
Nayeon Lee
KKKwang-Soo Kim
Kwang-Soo Kim
We report the implantation of patient-derived midbrain dopaminergic progenitor cells, differentiated in vitro from autologous induced pluripotent stem cells (iPSCs), in a patient with idiopathic Parkinson’s disease. The patient-specific progenitor cells were produced under Good Manufacturing Practice conditions and characterized as having the phenotypic properties of substantia nigra pars compacta neurons; testing in a humanized mouse model (involving peripheral-blood mononuclear cells) indicated an absence of immunogenicity to these cells. The cells were implanted into the putamen (left hemisphere followed by right hemisphere, 6 months apart) of a patient with Parkinson’s disease, without the need for immunosuppression. Positron-emission tomography with the use of fluorine-18-L-dihydroxyphenylalanine suggested graft survival. Clinical measures of symptoms of Parkinson’s disease after surgery stabilized or improved at 18 to 24 months after implantation. (Funded by the National Institutes of Health and others.)

17 December 2019 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
BSBin Song
Bin Song
YCYoung Cha
Young Cha
SKSanghyeok Ko
Sanghyeok Ko
JJJeha Jeon
Jeha Jeon
NLNayeon Lee
Nayeon Lee
KKKwang-Soo Kim
Kwang-Soo Kim
Parkinson's disease (PD) is a neurodegenerative disorder associated with loss of striatal dopamine, secondary to degeneration of midbrain dopamine (mDA) neurons in the substantia nigra, rendering cell transplantation a promising therapeutic strategy. To establish human induced pluripotent stem cell (hiPSC)-based autologous cell therapy, we report a platform of core techniques for the production of mDA progenitors as a safe and effective therapeutic product. First, by combining metabolism-regulating microRNAs with reprogramming factors, we developed a method to more efficiently generate clinical grade iPSCs, as evidenced by genomic integrity and unbiased pluripotent potential. Second, we established a “spotting”-based in vitro differentiation methodology to generate functional and healthy mDA cells in a scalable manner. Third, we developed a chemical method that safely eliminates undifferentiated cells from the final product. Dopaminergic cells thus produced express high levels of characteristic mDA markers, produce and secrete dopamine, and exhibit electrophysiological features typical of mDA cells. Transplantation of these cells into rodent models of PD robustly restores motor dysfunction and reinnervates host brain, while showing no evidence of tumor formation or redistribution of the implanted cells. We propose that this platform is suitable for the successful implementation of human personalized autologous cell therapy for PD.

12 July 2023 in Nature
Verified
Journal Article
Closed access
PDF file
TPTae-Yoon Park
Tae-Yoon Park
JJJeha Jeon
Jeha Jeon
NLNayeon Lee
Nayeon Lee
JKJisun Kim
Jisun Kim
BSBin Song
Bin Song
KKKwang-Soo Kim
Kwang-Soo Kim

1 December 2021 in Cell Reports
Verified
Journal Article
Open access
YCYoung Cha
Young Cha
TKTaewoo Kim
Taewoo Kim
JJJeha Jeon
Jeha Jeon
YJYongwoo Jang
Yongwoo Jang
PKPatrick B. Kim
Patrick B. Kim
KKKwang-Soo Kim
Kwang-Soo Kim
During somatic reprogramming, cellular energy metabolism fundamentally switches from predominantly mitochondrial oxidative phosphorylation toward glycolysis. This metabolic reprogramming, also called the Warburg effect, is critical for the induction of pluripotency, but its molecular mechanisms remain poorly defined. Notably, SIRT2 is consistently downregulated during the reprogramming process and regulates glycolytic switch. Here, we report that downregulation of SIRT2 increases acetylation of mitogen-activated protein kinase (MAPK) kinase-1 (MEK1) at Lys175, resulting in activation of extracellular signal-regulated kinases (ERKs) and subsequent activation of the pro-fission factor dynamin-related protein 1 (DRP1). In parallel, downregulation of SIRT2 hyperacetylates the serine/threonine protein kinase AKT1 at Lys20 in a non-canonical way, activating DRP1 and metabolic reprogramming. Together, our study identified two axes, SIRT2-MEK1-ERK-DRP1 and SIRT2-AKT1-DRP1, that critically link mitochondrial dynamics and oxidative phosphorylation to the somatic reprogramming process. These upstream signals, together with SIRT2’s role in glycolytic switching, may underlie the Warburg effect observed in human somatic cell reprogramming.